TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It calls for assessing function, nutrition and cognition before treatment and pairing medication with measures such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has published a case-based framework to guide clinicians considering obesity medications for older adults, including GLP-1 drugs. The paper urges assessment of functional ability, nutritional status and cognition before prescribing, reflecting concerns about frailty, muscle loss, malnutrition and dehydration in this age group.
Published in the Journal of the American Geriatrics Society, the paper applies the AGS Geriatrics 5Ms Framework to incretin therapies. Its five areas are Mind, Mobility, Medications, Multicomplexity and Matters Most. The authors present cases as a practical way to consider how these factors may shape treatment decisions for individual older patients.
The authors say clinicians should evaluate functional status, nutritional adequacy and cognitive impairment before starting treatment. They also recommend pairing medication with supportive measures, including resistance training and adequate dietary protein. For some patients, care may involve a registered dietitian, physical therapist, fitness trainer and behavioral health professional.
The article recognizes potential benefits of obesity medications for weight management and glycemic control, as well as other health conditions. It also notes that older adults are underrepresented in clinical trials, limiting how much evidence is available to guide prescribing in this population. The framework is intended to help clinicians weigh potential benefits alongside age-related risks, not to make a treatment decision for every patient.
Balancing Weight Treatment and Function
The framework addresses a practical prescribing challenge: weight loss may be a treatment goal, but clinicians also need to consider muscle strength, mobility and nutritional health in older adults. The AGS paper highlights risks including sarcopenia, frailty, lean muscle loss, malnutrition and dehydration that could affect a patient’s overall health and ability to function.
Its emphasis on pretreatment assessment and co-interventions places medication within a broader care plan. Considering exercise, protein intake and patient priorities may help clinicians tailor decisions rather than focusing on weight alone. The paper offers clinical guidance; the provided report does not establish that the framework has been tested in a trial or that it improves patient outcomes.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
Philips Sonicare DiamondClean 9900 Prestige Electric Toothbrush
Levoit Core 600S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
A Geriatrics Framework for Incretin Therapy
The paper was developed by the AGS Healthy Aging Special Interest Group and published in October 2026. Its focus is incretin therapy, including GLP-1 medications that act through gut-derived hormonal pathways. The authors use the existing Geriatrics 5Ms as an organizing structure for discussing the needs and circumstances of older patients.
The framework comes as obesity medications are used for weight management and may offer benefits related to blood sugar control and other conditions. But the source report stresses that older adults have been underrepresented in clinical trials. That evidence gap makes careful attention to age-related health factors important when applying findings and treatment approaches to older patients.
“Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing”
— Elias M. Wisdom and co-authors
Evidence Gaps and Patient Outcomes
The source report does not give trial results showing whether use of the framework changes prescribing decisions or improves health outcomes. It also does not specify which obesity medications, doses or patient profiles should be preferred, or provide detailed clinical thresholds for assessing risks such as frailty and muscle loss.
Because older adults are underrepresented in clinical trials, the strength of evidence for medication effects and risks in this population remains a concern identified by the paper. The report does not say how widely clinicians have adopted the framework or whether additional studies are planned.
Applying the Guidance in Clinical Care
The paper offers clinicians a structured approach for discussing and assessing obesity medication use in older adults. In practice, its recommendations point toward individual assessment before prescribing, attention to nutrition and function during care, and coordination with other professionals when a patient’s needs warrant it.
The provided source does not announce a rollout schedule, implementation program or follow-up study. Further evidence about outcomes in older adults, alongside clinical experience applying the 5Ms approach, will be needed to clarify how the framework affects care. Treatment decisions remain specific to each patient and should be made with qualified clinicians.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians considering obesity medications in older adults. It applies the Geriatrics 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin therapy.
What should clinicians assess before prescribing?
The paper recommends assessing functional status, nutritional adequacy and cognitive impairment. It also highlights age-related concerns such as frailty, sarcopenia, muscle loss, malnutrition and dehydration.
What supportive measures does the framework recommend?
The authors recommend pairing treatment with measures such as resistance training and adequate dietary protein. Some older adults may benefit from a team that includes nutrition, physical therapy, fitness and behavioral health professionals.
Does the framework prove obesity medications are safe for all older adults?
No. The paper provides a prescribing approach, not proof of safety for every patient. The source report notes that older adults are underrepresented in clinical trials, and treatment decisions require individual clinical assessment.
Source: medicalxpress.com
